OLMA

Rating neutralTentativeAI Memo

Olema

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

OPERA-01 Phase 3 top-line data • 2027-03-31

Base target: $8 / p=0% prob

Biggest risk

An unfavorable or delayed OPERA-01 readout would undermine the lead program. Second-quarter 2026 net loss rose to $63.2 million from $43.8 million a year earlier as development and corporate spending increased [#SEC-8K-2026-08-10].

Invalidation

Break below $4 or thesis failure.

What would change my mind?

A favorable OPERA-01 efficacy and safety readout could support palazestrant's development and potential launch plans. Olema reported $461.1 million in cash, cash equivalents and marketable securities at June 30, 2026, providing resources for ongoing trials [#SEC-8K-2026-08-10].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-02

Base target

p=0%

Bull target

$17

p=0%

Bear target

p=1%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Oral-SERD competitor read-through
OP-3136 and Bayer study initiation
A favorable OPERA-01 efficacy and safety readout could support palazestrant's development and potential launch plans.

BearKey bullets

Higher R&D spending and a $63.2 million second-quarter net loss create continuing cash-consumption and eventual financing risk despite the reported $461.1 million cash and securities balance [#SEC-8K-2026-08-10].
OP-3136 remains early-stage; study initiation and initial Phase 1 observations do not establish registrational efficacy [#SEC-8K-2026-08-10].
OPERA-01 has binary efficacy and safety risk; competitor trial outcomes cannot substitute for palazestrant-specific data.

WatchKey bullets

OPERA-01 Phase 3 top-line data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=0%)

Target spread vs base: +127% / -53%

Scenario probabilities

Bull Target: $17 (p=0%)Base Target: $8 (p=0%)Bear Target: $4 (p=1%)

Commentary

Cautious monitoring view, consistent with the packet's negative directional prior and limited coverage. A stored third-party article reported a 15.1% premarket fall on September 14 following SERENA-4; that is not a verified closing-price reaction. Roche's October 1 evERA update complicates a uniformly negative oral-SERD read-through, but no Olema-specific price reaction to it was verified. Analyst-revision coverage is thin. Social, options, short-interest and employee measures were not supplied; their zero entries denote unavailable data, not neutral readings. The August 13 8-K note establishes a filing date but supplies no substantive operating update [#8-K-2026-08-13].

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Oral-SERD competitor read-through
OP-3136 and Bayer study initiation

Scenarios

Bull Target (Scenario probability)

$17 / p=0% prob

Base Target (Scenario probability)

$8 / p=0% prob

Bear Target (Scenario probability)

$4 / p=1% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
OPERA-01 Phase 3 top-line data
Olema completed enrollment and expects top-line data for palazestrant monotherapy in second- or third-line ER-positive, HER2-negative metastatic breast cancer in Q1 2027. Efficacy and safety are the principal binary value drivers. March 31 marks the end of the company's stated window, not an announced release date; the probability estimates a readout within that window, not trial success [#SEC-8K-2026-08-10].
Prob 80.00% • Move 30.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Oral-SERD competitor read-through
2026-10-31
AstraZeneca's first-line SERENA-4 combination trial missed its primary endpoint, while Roche reported positive results for its distinct later-line evERA combination trial. These results may influence sentiment but do not establish the outcome of Olema's palazestrant monotherapy trial [#PR-AZN-2026-09-11] [#PR-ROCHE-2026-10-01]. Sources: https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html and https://www.roche.com/media/releases/med-cor-2026-10-01
Prob 60% • Move -5% • Priced-in 70%

Long-term Catalysts

Months to a year

OP-3136 and Bayer study initiation
2026-12-31
Olema anticipated starting enrollment in a Phase 1b/2 study of OP-3136 plus darolutamide in Q4 2026. Initiation would demonstrate development execution, not clinical efficacy [#SEC-8K-2026-08-10].
Prob 65% • Move 4% • Priced-in 40%

Risks

Higher R&D spending and a $63.2 million second-quarter net loss create continuing cash-consumption and eventual financing risk despite the reported $461.1 million cash and securities balance [#SEC-8K-2026-08-10].
OP-3136 remains early-stage; study initiation and initial Phase 1 observations do not establish registrational efficacy [#SEC-8K-2026-08-10].
OPERA-01 has binary efficacy and safety risk; competitor trial outcomes cannot substitute for palazestrant-specific data.
The Q1 2027 readout window may slip, extending uncertainty [#SEC-8K-2026-08-10].

Peers

Symbol	Summary
AZN	Relevant oral-SERD clinical comparator, not a market-cap peer. SERENA-4 tested first-line camizestrant plus palbociclib, whereas OPERA-01 tests later-line palazestrant monotherapy; its miss is a sentiment read-through, not evidence that OPERA-01 will fail [#PR-AZN-2026-09-11].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

AZN

Relevant oral-SERD clinical comparator, not a market-cap peer. SERENA-4 tested first-line camizestrant plus palbociclib, whereas OPERA-01 tests later-line palazestrant monotherapy; its miss is a sentiment read-through, not evidence that OPERA-01 will fail [#PR-AZN-2026-09-11].